StreetInsider.com News Articles

Form 144 ADMA BIOLOGICS, INC. Filed by: Tade Brad L.

Tue, 10 Mar 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260310/26141447.html

Form 144 ADMA BIOLOGICS, INC. Filed by: Tade Brad L.

Tue, 10 Mar 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260310/26141447.html

Form 4 ADMA BIOLOGICS, INC. For: Mar 06 Filed by: Grossman Adam S

Tue, 10 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260310/26141375.html

Form 4 ADMA BIOLOGICS, INC. For: Mar 06 Filed by: Grossman Adam S

Tue, 10 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260310/26141375.html

Form 4 ADMA BIOLOGICS, INC. For: Mar 06 Filed by: Kestenberg-Messina Kaitlin M.

Tue, 10 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260310/26141378.html

Form 4 ADMA BIOLOGICS, INC. For: Mar 06 Filed by: Kestenberg-Messina Kaitlin M.

Tue, 10 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260310/26141378.html

Form 144 ADMA BIOLOGICS, INC. Filed by: Kestenberg-Messina Kaitlin M.

Mon, 09 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260309/26134016.html

Form 144 ADMA BIOLOGICS, INC. Filed by: Kestenberg-Messina Kaitlin M.

Mon, 09 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260309/26134016.html

Form 4 ADMA BIOLOGICS, INC. For: Mar 05 Filed by: ELMS STEVE

Mon, 09 Mar 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260309/26129848.html

Form 4 ADMA BIOLOGICS, INC. For: Mar 05 Filed by: ELMS STEVE

Mon, 09 Mar 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260309/26129848.html

Form 4 ADMA BIOLOGICS, INC. For: Feb 26 Filed by: Grossman Adam S

Mon, 02 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260302/26094852.html

Form 4 ADMA BIOLOGICS, INC. For: Feb 26 Filed by: Grossman Adam S

Mon, 02 Mar 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260302/26094852.html

Form 8-K ADMA BIOLOGICS, INC. For: Mar 02

Mon, 02 Mar 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260302/26086849.html

Form 8-K ADMA BIOLOGICS, INC. For: Mar 02

Mon, 02 Mar 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260302/26086849.html

ADMA Biologics announces $125 million share buyback with JPMorgan

Mon, 02 Mar 2026 07:00:17 -0400

ADMA Biologics Inc. (NASDAQ: ADMA) announced a $125 million accelerated share repurchase agreement with JPMorgan Chase Bank as part of a planned $200 million capital return initiative for 2026.

Under the agreement, ADMA will pay JPMorgan $125 million upfront and initially receive approximately 6.4 million shares of its common stock on March 3, 2026. This represents about 80% of the shares expected to be repurchased under the accelerated share repurchase program, based on the closing price of $15.57 per share on February 27, 2026.

The total number of shares ultimately repurchased will be determined by the average daily volume-weighted average price of

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

Mon, 02 Mar 2026 07:00:00 -0400

RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association (“JPMorgan”). The initiative underscores the Company’s strong financial position, durable free cash flow profile and confidence in its long-term growth trajectory.

“We believe ADMA’s common stock represents the

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

Mon, 02 Mar 2026 07:00:00 -0400

“We believe ADMA’s common stock represents the

Form 3 ADMA BIOLOGICS, INC. For: Feb 26 Filed by: Kohler Terry

Thu, 26 Feb 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260226/26073679.html

Form 3 ADMA BIOLOGICS, INC. For: Feb 26 Filed by: Kohler Terry

Thu, 26 Feb 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260226/26073679.html

ADMA Biologics (ADMA) Tops Q4 EPS by 1c ; Offers Guidance

Thu, 26 Feb 2026 00:50:47 -0400

ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of $0.20, $0.01 better than the analyst estimate of $0.19. Revenue for the quarter came in at $139.16 million versus the consensus estimate of $139.85 million.

GUIDANCE:

ADMA Biologics sees FY2026 revenue of ~$635 million, versus the consensus of $635 million.

ADMA Biologics sees FY2027 revenue of ~$775 million, versus the consensus of $775 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

ADMA Biologics (ADMA) Tops Q4 EPS by 1c ; Offers Guidance

Thu, 26 Feb 2026 00:50:47 -0400

GUIDANCE:

ADMA Biologics sees FY2026 revenue of ~$635 million, versus the consensus of $635 million.

ADMA Biologics sees FY2027 revenue of ~$775 million, versus the consensus of $775 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

Form 10-K ADMA BIOLOGICS, INC. For: Dec 31

Wed, 25 Feb 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260225/26061656.html

Form 10-K ADMA BIOLOGICS, INC. For: Dec 31

Wed, 25 Feb 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260225/26061656.html

Form 8-K ADMA BIOLOGICS, INC. For: Feb 20

Wed, 25 Feb 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260225/26060019.html

Form 8-K ADMA BIOLOGICS, INC. For: Feb 20

Wed, 25 Feb 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260225/26060019.html